Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Loki zupa is a traditional Uighur medicine (TUM) formulation investigated for the treatment of bronchial asthma, particularly in patients diagnosed with abnormal phlegmatic temperament according to Uighur medical theory. Developed and studied by researchers at Huashan Hospital of Fudan University, the drug is a complex herbal compound typically administered as an oral decoction or syrup. It is hypothesized to work by modulating inflammatory responses in the airways and facilitating the clearance of phlegm. Clinical research, including multicenter randomized controlled trials, has focused on its ability to improve lung function and quality of life when used as a complementary therapy to standard asthma management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Loki zupa (Huashan Hospital).